Mirum Pharma 2024 net sales ~$336M, above guidance; 2025 outlook $420-435M

Mirum Pharmaceuticals, Inc.

2024-FY EPS reported -$1.85 revenue$336,888,000

Preliminary unaudited FY2024 net product sales ~$336M, exceeding upper end of guidance range.
LIVMARLI net sales ~$213M; CHOLBAM/CHENODAL ~$123M; Q4 2024 sales ~$99M.
2025 guidance: global net product sales $420-435M with positive cash flow from operations.
Year-end cash and investments ~$287M; achieved positive cash from operations in Q3 2024.
Pipeline: PDUFA date for chenodiol in CTX March 28, 2025; volixibat VISTAS enrollment completion H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.